Microport Scientific Corp. · HKEX:853
Microport Scientific — FY2022 Earnings Presentation
29 slides from Microport Scientific's earnings presentation, Mar 31, 2023
Slide 1: MicroPort Scientific Corporation 2022 Annual Results
MicroPort Scientific Corporation 2022 Annual Results March 2023
Slide 2: Disclaimer
2022 Annual Results Disclaimer 31 March 2023 This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no pa
Slide 3: Contents
Contents 1 Company Highlights 2 Business Review 3 Financial Review 4 Outlook 5 Appendix – Financial Statements
Slide 4: Ambitious pursuit of innovation for 25 consecutive years
2022 Annual Results Ambitious pursuit of innovation for 25 consecutive years 31 March 2023 Core Business Total cardio solutions Other sectors covering main clinical specialties Global leading Partnerships with global Unswervingly medical devices Uncompromising in Industry leading leading KOLs and in
Slide 5: Outstanding performance amid lingering COVID affect in China
2022 Annual Results Outstanding performance amid lingering COVID affect in China 31 March 2023 2022 Highlights Revenue $ 840.8mn 15.6%YOY Orthopedics Others1 $ 233.6mn 9.5%YOY $ 21.4mn 1284.4%YOY Non-China +10.3% CRM Surgical devices $ 204.2mn 3.5%YOY $ 4.5mn China +6.7% Surgical robot Cardiovascula
Slide 6: Strong operating performance in 2022 across all businesses
2022 Annual Results Strong operating performance in 2022 across all businesses 31 March 2023 Business highlights1 R&D achievements Total-cardio • International revenue ↑60% YOY, intl. DES revenue up 63% YOY • Firehawk® clinical trials (for FDA assessment) • Beyond Prefer™ guide wire obtained NMPA; s
Slide 7: Global business developed rapidly through geographic diversity
2022 Annual Results Global business developed rapidly through geographic diversity 31 March 2023 Global Strategic Triangle EMEA Asia¹ Americas ↑ 13% YOY ↑ 20% YOY ↑ 6% YOY Revenue growth Revenue growth Revenue growth South Korea • Endo: Minos® approved • Neuro: NUMEN® approved US & commercialized •
Slide 8: Contents
Contents 1 Company Highlights 2 Business Review 3 Financial Review 4 Outlook 5 Appendix – Financial Statements
Slide 9: Cardiovascular business
2022 Annual Results Cardiovascular business 31 March 2023 Business highlights • 2022 revenue $134.1mn, up 2% YOY, despite the incessant impact of the pandemic Revenue Overview • Guaranteed DES volume doubled in the continued procurement of VBP (v.s. 2020); newly approved Firebird Pro+® win the bid;
Slide 10: Orthopedics business
2022 Annual Results Orthopedics business 31 March 2023 Non-China business China business Revenue Breakdown by region Revenue Half year revenue USD: million USD: million +10% +3% +68% EMEA 32% 202.4 Revenue growth 22.3 21.1 EMEA: ↑ 33% US 41% 2022 11.1 193.3 Japan 8.0 17% Others 10% 2021 2022 2021 20
Slide 11: CRM business
2022 Annual Results CRM business 31 March 2023 Non-China business China business Revenue Revenue USD: million +3% USD: million +7% Top 1 Chinese player 206.8 191.1 One of the 13.6 13.1 No. 1 ONLY 5 market share for China-made products multi-national players 2021 2022* 2021 2022* * due to enormous de
Slide 12: Endovascular business
2022 Annual Results Endovascular business 31 March 2023 Business highlights Product pipeline Key Financials Product Pre-clinical Clinical Registration USD: million +31% 2021 2022 133.2 Talos® Thoracic 107.0 +14% +12% Stent Graft NMPA approved System 57.1 63.6 47.8 52.4 Aortics Cratos® Branched Ste
Slide 13: Neurovascular business
2022 Annual Results Neurovascular business 31 March 2023 • Successfully listed on HKEx on July 15, 2022 Product Pre-clinical Clinical Registration 2172.HK • Becoming the 4th subsidiary to accomplish public listing NUMEN Silk™ 3D Electro- NMPA approved nically Detachable Coil Revenue Revenue Breakd
Slide 14: Heart valve business
2022 Annual Results Heart valve business 31 March 2023 Business highlights Product pipeline Revenue Gross profit margin Product Pre-clinical Clinical Registration USD: million +22% +626% +6ppts VitaFlow Liberty™ • CE marking in progress 2021 35.8 1.0 64.6% TAVI VitaFlow™ III • Approaching design fre
Slide 15: Surgical robot business
2022 Annual Results Surgical robot business 31 March 2023 Business highlights Product Pre-clinical Clinical Registration Toumai® Laparoscopic Obtained NMPA • 2022 revenue $3.1mn, up 904.8% YOY, thanks to the 1st commercial Surgical Robot (“Toumai®”) installation of Toumai®, as well as rapid sales
Slide 16: Surgical devices business
2022 Annual Results Surgical devices business 31 March 2023 Product Pre-clinical Clinical Registration • Provider of complete and systematic life support solutions for acute Obtained CE mark Hemovent1 MOBYBOX® ECMO transport system critical cases, product portfolio includes ECMO system, oxygenator
Slide 17: Emerging business - medical imaging
2022 Annual Results Emerging business - medical imaging 31 March 2023 Pre- Registrat Product Indication Clinical clinical ion • Provide total precise interventional imaging solution, multifaceted coverage including panvascular (cardiovascular, neurovascular, and Obtained NMPA approval Insight-100
Slide 18: Emerging business - urinary, gynecological, digestive & respiratory business
2022 Annual Results Emerging business - urinary, gynecological, digestive & respiratory 31 March 2023 business Pre- Registrat Product Indication Clinical clinical ion • Provide innovative total solutions in endoscope and disposal devices to urological, gastrointestinal, gynecological & respiratory d
Slide 19: Emerging business
2022 Annual Results Emerging business 31 March 2023 Business highlights Materials & intelligent manufacturing service1 2022 revenue increased by 37% YOY with profitability Provide world’s leading solutions incl. upstream raw material, CDMO and testing TOP 1 Chinese 3D catheter RF ablation play
Slide 20: Contents
Contents 1 Company Highlights 2 Business Review 3 Financial Review 4 Outlook 5 Appendix – Financial Statements
Slide 21: Consolidated Financial Performance
2022 Annual Results Consolidated Financial Performance 31 March 2023 Revenue Gross profit margin USD: million +15.6% 840.8 63.2% 59.7% 778.6 2021 2022 2021 2022 Operating expenses Total net loss & net loss attributable to equity shareholders USD: million USD: million Net loss attributable to equity
Slide 22: Operating Expenses
2022 Annual Results Operating Expenses 31 March 2023 Sales & marketing expenses Administrative expenses R&D expenses USD: million USD: million USD: million 400 40.0% 60.0% 450.0 50.0% 500 50.0% 400.0 45.0% 350 32.1% 35.0% 50.0% 38.2% 39.1% 29.5% 350.0 40.0% 300 30.0% 400 38.2% 35.0% 40.0% 300.0 250
Slide 23: Contents
Contents 1 Company Highlights 2 Business Review 3 Financial Review 4 Outlook 5 Appendix – Financial Statements
Slide 24: Innovative product pipeline fueling long-term growth
2022 Annual Results Innovative product pipeline fueling long-term growth 31 March 2023 Firesorb® Coronary Rotational Coronary Intravascular Micro- Scoring Coronary Stent Graft Cardio- Anchor Balloon Bioresorbable Atherectomy Rapamycin Firehawk® Lithotripsy catheter Balloon System vascular NMPA Scaff
Slide 25: Contents
Contents 1 Company Highlights 2 Business Review 3 Financial Review 4 Outlook 5 Appendix – Financial Statements
Slide 26: Appendix I - Consolidated Income Statement
2022 Annual Results Appendix I - Consolidated Income Statement 31 March 2023 USD'000 2022 2021 Var. Revenue 840,831 778,639 8.0% Cost of sales (339,060) (286,866) 18.2% Gross profit 501,771 491,773 2.0% Other net income 36,150 76,475 -52.7% Research and development costs (419,828) (297,778) 41.0% Di
Slide 27: Appendix II - Consolidated Balance Sheet
2022 Annual Results Appendix II - Consolidated Balance Sheet 31 March 2023 USD'000 31 Dec 2022 31 Dec 2021 Var. Non-current assets Investment properties 6,579 7,407 -11% Other property, plant and equipment 993,014 922,874 8% Intangible assets 223,683 256,609 -13% Goodwill 262,829 290,565 -10% Equity
Slide 28: Appendix II - Consolidated Balance Sheet
2022 Annual Results Appendix II - Consolidated Balance Sheet 31 March 2023 Interest-bearing borrowings 336,689 269,637 25% Lease liabilities 124,373 168,437 -26% Deferred income 38,123 35,098 9% Convertible bonds 769,553 660,369 17% Contract liabilities 24,839 26,243 -5% Other payables 220,997 425,9
Slide 29: Disclaimer
2022 Annual Results Disclaimer 31 March 2023 This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no pa